FFA
PTGX icon

Farther Finance Advisors’s Protagonist Therapeutics PTGX Stock Holding History

Farther Finance Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$338K Buy
2,398
+1,956
+443% +$279K ﹤0.01% 1893
2026
Q2 		$54.2K Buy
442
+109
+33% +$11.4K ﹤0.01% 3191
2026
Q1 		$34.5K Buy
333
+36
+12% +$3.19K ﹤0.01% 3257
2025
Q4 		$25.9K Buy
297
+156
+111% +$12.8K ﹤0.01% 3261
2025
Q3 		$9.37K Buy
141
+48
+52% +$2.73K ﹤0.01% 3468
2025
Q2 		$5.14K Sell
93
-296
-76% -$14.2K ﹤0.01% 3346
2025
Q1 		$18.2K Buy
389
+345
+784% +$14.5K ﹤0.01% 2426
2024
Q4 		$1.7K Hold
44
– – ﹤0.01% 3058
2024
Q3 		$1.98K Sell
44
-1
-2% -$40 ﹤0.01% 2997
2024
Q2 		$1.58K Buy
45
+5
+13% +$146 ﹤0.01% 2885
2024
Q1 		$1.13K Hold
40
– – ﹤0.01% 2723
2023
Q4 		$917 Buy
+40
New +$700 ﹤0.01% 2771

Other funds holding PTGX

FSA
Franklin Street Advisors Chapel Hill, North Carolina $1.82B AUM 22.19% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
HIA
Harbor Investment Advisory Lutherville, Maryland $1.47B AUM 24.2% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
CIA
Cape Investment Advisory Mcdonough, Georgia $388M AUM 17.15% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.66B AUM 13.15% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
MAM
Marquette Asset Management Minneapolis, Minnesota $766M AUM 16.04% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $148M AUM 25.13% 1-Year Est. Return

Farther Finance Advisors's PTGX Position: Q3 2026 in Review

Farther Finance Advisors increased its Protagonist Therapeutics (PTGX) stake by 443% in Q3 2026, buying an estimated $279K and bringing the position to 2,398 shares worth $338K. The position accounts for ﹤0.01% of the portfolio, ranked #1893.

Farther Finance Advisors first reported a position in PTGX in Q4 2023 and has held it in 12 quarters since. 14 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.

  • Farther Finance Advisors held 2,398 shares of Protagonist Therapeutics worth $338K as of Q3 2026.
  • Farther Finance Advisors bought 1,956 Protagonist Therapeutics shares in Q3 2026, an estimated $279K.
  • Protagonist Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #1893 holding.
  • Farther Finance Advisors first reported a position in Protagonist Therapeutics in Q4 2023 and has held it in 12 quarters since.
  • 14 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.